The vernal keratoconjunctivitis market was valued at USD 463.55 Million in 2024, driven by advances in treatment options across the 8 major markets. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034, with the values likely to reach USD 838.01 Million by 2034.
Base Year
Historical Year
Forecast Year
In February 2024, Harrow, Inc., a United States-based eye care pharmaceutical company, and Apotex Inc., a Canadian pharmaceutical corporation, formed an exclusive partnership to promote VERKAZIA®, a treatment for vernal keratoconjunctivitis, to enhance access and expand the market reach.
The ongoing research and development efforts to improve treatment options for vernal keratoconjunctivitis are expected to increase market growth.
The rise in new drug approvals by regulatory agencies like the United States FDA is a significant market trend.
Value in USD Million
2025-2034
Vernal Keratoconjunctivitis Market Outlook
*this image is indicative*
Vernal keratoconjunctivitis is a long-lasting allergic condition triggered by sensitivity to allergens found in the air. Younger males are the ones that are more commonly affected, showing symptoms like itching, sensitivity to light, redness, and discharge of mucus. The rise in vernal keratoconjunctivitis cases, especially in adults, is driving the market growth. Additionally, there is a growing preference for using immunomodulatory therapies, which are poised to impact the market dynamics in the forecast period.
Increasing Recognition of Vernal Keratoconjunctivitis Cases in Adults to Drive Market Growth
The market for vernal keratoconjunctivitis is expanding as more adult cases are identified. A United States-based study demonstrated that approximately 10% of cases persist into adulthood or arise post-puberty, broadening the patient population and necessitating new treatments to address issues, thereby stimulating market expansion.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment:
Market Breakup by Dosage Form:
Market Breakup by Distribution Channel:
Market Breakup by Region:
Segmentation Based on Treatment to Witness Substantial Growth
Based on the treatment, the market is segmented into nonsteroidal anti-inflammatory drugs – NSAIDs, mast cell stabilizers, antihistamines, topical corticosteroids, cyclosporine, and others. Topical corticosteroids are expected to dominate the market share as they remain the most widely used option due to their effectiveness in rapidly reducing inflammation and alleviating symptoms like itching, pain, and sensitivity to light.
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is one of the leading markets owing to the high prevalence of conjunctivitis, coupled with an increased demand for effective treatments. With improved healthcare services and accessibility, the United States market for vernal keratoconjunctivitis is projected to witness significant growth in the coming years.
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Santen Pharmaceutical, is a Japanese company specialized specializing in ophthalmology, was granted FDA authorization in June 2021, for Verkazia, an eye drop medication containing cyclosporine, to manage vernal keratoconjunctivitis.
Novartis is a cutting-edge pharmaceutical company that introduced ALOMIDE eye drops for managing vernal keratoconjunctivitis, stopping allergic responses by inhibiting mast cells from releasing inflammatory substances.
Senju Pharmaceutical Co., Ltd., headquartered in Japan, has a prominent presence in the market. The company specializes in ophthalmology, boasting a robust portfolio of medications for managing allergic conjunctivitis and vernal keratoconjunctivitis.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Akari Therapeutics Plc., Allakos Inc., Satellos Bioscience Inc., Viatris Inc., Aldeyra Therapeutics, Inc., Laboratoires Thea S.A.S., and Astellas Pharma Inc.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment |
|
| Breakup by Dosage Form |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share